BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27812140)

  • 1. Early Outcomes Of Decentralized Care for Rifampicin-Resistant Tuberculosis in Johannesburg, South Africa: An Observational Cohort Study.
    Berhanu R; Schnippel K; Mohr E; Hirasen K; Evans D; Rosen S; Sanne I
    PLoS One; 2016; 11(11):e0164974. PubMed ID: 27812140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
    Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
    BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.
    Wu Z; Rueda ZV; Li T; Zhang Z; Jiang Y; Sha W; Yu F; Chen J; Pan Q; Shen X; Yuan Z
    BMC Infect Dis; 2020 Feb; 20(1):153. PubMed ID: 32070292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective Diagnostic Accuracy Study of Abbott RealTi
    Howlett P; Nabeta P; Tukvadze N; Schumacher SG; Denkinger CM
    Microbiol Spectr; 2021 Sep; 9(1):e0013221. PubMed ID: 34406811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa.
    Hanrahan CF; Selibas K; Deery CB; Dansey H; Clouse K; Bassett J; Scott L; Stevens W; Sanne I; Van Rie A
    PLoS One; 2013; 8(6):e65421. PubMed ID: 23762367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis in a high HIV prevalence setting.
    Theron G; Peter J; van Zyl-Smit R; Mishra H; Streicher E; Murray S; Dawson R; Whitelaw A; Hoelscher M; Sharma S; Pai M; Warren R; Dheda K
    Am J Respir Crit Care Med; 2011 Jul; 184(1):132-40. PubMed ID: 21493734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.
    Lawn SD; Brooks SV; Kranzer K; Nicol MP; Whitelaw A; Vogt M; Bekker LG; Wood R
    PLoS Med; 2011 Jul; 8(7):e1001067. PubMed ID: 21818180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Sohn H; Schiller I; Kloda LA; Boehme CC; Pai M; Dendukuri N
    Cochrane Database Syst Rev; 2013 Jan; (1):CD009593. PubMed ID: 23440842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.
    Shapiro AE; Ross JM; Yao M; Schiller I; Kohli M; Dendukuri N; Steingart KR; Horne DJ
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013694. PubMed ID: 33755189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
    van Kampen SC; Tursynbayeva A; Koptleuova A; Murzakhmetova Z; Bigalieva L; Aubakirova M; Pak S; van den Hof S
    PLoS One; 2015; 10(7):e0132514. PubMed ID: 26181578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upfront Xpert MTB/RIF testing on various specimen types for presumptive infant TB cases for early and appropriate treatment initiation.
    Raizada N; Khaparde SD; Rao R; Kalra A; Sarin S; Salhotra VS; Swaminathan S; Khanna A; Chopra KK; Hanif M; Singh V; Umadevi KR; Nair SA; Huddart S; Tripathi R; Surya Prakash CH; Saha BK; Denkinger CM; Boehme C
    PLoS One; 2018; 13(8):e0202085. PubMed ID: 30161142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and Outcomes.
    Katende B; Esterhuizen TM; Dippenaar A; Warren RM
    Sci Rep; 2020 Feb; 10(1):1917. PubMed ID: 32024860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study.
    Boehme CC; Nicol MP; Nabeta P; Michael JS; Gotuzzo E; Tahirli R; Gler MT; Blakemore R; Worodria W; Gray C; Huang L; Caceres T; Mehdiyev R; Raymond L; Whitelaw A; Sagadevan K; Alexander H; Albert H; Cobelens F; Cox H; Alland D; Perkins MD
    Lancet; 2011 Apr; 377(9776):1495-505. PubMed ID: 21507477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.